[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-embolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-embolism":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,59,0,25,[9,46,79,114,147,170,195,220,240,262,284,305,332,352,377,394,427,447,470,489,515,540,566,594,632],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100550960","phase-3-percutaneous-embolectomy-low-dose-thrombolysis-or-heparin-for-intermediate-high-risk-pulmonary-embolism-stratify-ii-100550960",false,"NCT06453876","Percutaneous Embolectomy, Low Dose Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY II)","STRATIFY-II","INCLUSION CRITERIA\n\n1. Age ≥ 18 years\n2. Intermediate high-risk PE according to ESC criteria\n3. Class II risk assessed by the Pulmonary Embolism Severity Index (1).\n4. Thrombus visible in main, lobar or segmental pulmonary arteries on CT angiography\n5. 14 days of symptoms or less, with significant worsening of symptoms within 7 days\n\nEXCLUSION CRITERIA\n\n1. Altered mental state (GCS \\\u003C 14)\n2. No qualifying CT angiography performed (\\> 24 hour since CT angiography)\n3. Women of childbearing potential, unless negative HCG test is present.\n4. Thrombolysis for PE within 14 days of randomization\n5. Thrombus passing through patent Foramen Ovale (risk of paradoxical embolism)\n6. Ongoing oral anticoagulation therapy (heparins, aspirin, antiplatelet therapy and NOAC allowed)\n7. Comorbidity making 6 months survival unlikely.\n8. Absolute contraindications for thrombolysis:\n\n   1. History of haemorrhagic stroke or stroke of unknown origin\n   2. Ischaemic stroke in previous 6 months\n   3. Central nervous system neoplasm\n   4. Major trauma, surgery, or head injury in previous 3 weeks\n   5. Bleeding diathesis - Active bleeding","ALL","18 Years",{"count":20,"type":21},210,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The STRATIFY II trial investigates the efficacy of three different approaches to reducing thrombus burdon in patients with acute intermediate high-risk pulmonary embolism: percutaneous embolectomy (the AlphaVAC(R), AngioDynamics or the Flow Triever® system, INARI medical), Low intravenous thrombolysis (Alteplase 10 mg) and heparin with the option to perform full-dose thrombolysis. As a co-primary secondary end point the trial assess the incremental efficacy of the embolectomy vs the catheter based low dose thrombolysis approach.\n\nThus the two main hypothesis being tested are:\n\n1. Thrombus burden reduction after 48-96 h is increased with a catheter based (embolectomy or low-dose alteplase) compared to the a heparin with optional high dose thrombolysis approach (1st co-primary outcome)\n2. Thrombus burden reduction after 48-96 h is increased with percutaneous embolectomy compared to low-dose alteplase (2nd co-primary outcome)",[27],"Pulmonary Embolism",[29,30,31,32],"Randomized Clinical Trial","Pulmonary embolism","embolectomy","thrombolysis","RECRUITING","2026-07-01",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2026-06-17",{"date":41,"type":21},"2029-10-31",{"name":43,"class":44},"Jesper Kjaergaard","OTHER",2,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100619890","aspiration-thrombectomy-using-the-symphony-or-prodigy-system-100619890","NCT07350499","Aspiration Thrombectomy Using the Symphony or Prodigy System","Long-Term CLinical Evaluation of Aspiration ThRombectomy Using the Symphony or ProdIgy Thrombectomy System - CLEAR-IT","CLEAR-IT","Inclusion Criteria:\n\n1. Subject is ≥ 18 years of age\n2. Subject is willing and able to comply with the follow-up schedule specified in this protocol\n3. Subject is willing and able to provide written informed consent prior to any study-related data collection\n4. Subject has a planned procedure, involving the use of Imperative Care vascular devices within their intended use\n\nExclusion Criteria:\n\n1. Subjects with any contraindications per the applicable Instructions for Use\n2. Subject with life expectancy of less than 1 year\n3. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with Imperative Care devices\n4. Subject who may be unable to complete study follow-up\n5. Peripheral Venous Cohort ONLY: Presence of thrombus extending more than 2 cm into the IVC on imaging",{"count":55,"type":21},750,"OBSERVATIONAL","The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.",[59,60,27],"Arterial Thromboembolism","Venous Thromboembolism",[27,62,63,64,65,66,67],"Thrombus","Thromboembolism","Aspiration","Aspiration thrombectomy","Anticoagulation","Peripheral vasculature","2026-06-23",{"date":70,"type":37},"2026-06-26",{"date":72,"type":37},"2026-02-13",{"date":74,"type":21},"2030-09",{"name":76,"class":77},"Imperative Care, Inc.","INDUSTRY",4,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100531111","phase-3-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-lower-limb-trauma-requiring-brace-or-casting-100531111","NCT06195540","RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST : RIVAroxaban Versus Low-molecular Weight Heparinin Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST","Inclusion Criteria:\n\n* Patient aged 18 or over ;\n* Consultation in an emergency department of a participating centre;\n* Trauma to the lower limb requiring rigid or semi-rigid orthopaedic immobilisation;\n* Expected duration of orthopaedic immobilisation of at least 2 weeks;\n* TRiP(cast) score ≥ 7 ;\n* Patient affiliated to or benefiting from a social security scheme;\n* Patient with prior informed consent.\n\nExclusion Criteria:\n\n* Patient that have to be hospitalized after emergency department for other reason than lower limb trauma\n* Active bleeding or high risk of bleeding,\n* Known contraindication to rivaroxaban or LMWH;\n* Taking any anticoagulant or antiplatelet agent before the trauma (only antithrombotic authorised: aspirin \\\u003C 325mg\u002Fd);\n* Pregnant or breastfeeding woman;\n* Any factor making 3-month follow-up impossible; 6. Patient subject to a legal protection measure, Imprisonment 7. Participation in any interventional study which modifies patient care or could influence study evaluation criteria",{"count":88,"type":21},1424,[24],"Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE). The TRiP(cast) score has been developed to provide individual VTE risk stratification and help in thromboprophylactic anticoagulation decision. The recent CASTING study had confirmed that patients with a TRiP(cast) score \\\u003C7 have a very low risk of VTE and could be safely manage without prophylactic treatment. Conversely, patients with a score ≥ 7 have a high-risk of VTE and require a prophylactic anticoagulant treatment. Low molecular weight heparins (LMWH) have been shown to be effective in this indication. However, in the CASTING study, the 3-month symptomatic VTE rate was 2.6% in this subgroup despite LMWH prophylactic treatment. This result suggests that LMWH are not sufficiently effective in this particular subgroup of high-risk patients. Direct oral anticoagulants, and in particular rivaroxaban, may be an effective and safe alternative to LMWH. In the PRONOMOS study, comparing LMWH with rivaroxaban in patients who had undergone non-major lower limb surgery, the relative risk of symptomatic VTE was 0.25 (95% CI = 0.09 - 0.75) in favor of rivaroxaban 10mg. No significant increase in bleeding was found. In addition, as LMWH treatment requires subcutaneous daily injections, the use of rivaroxaban may positively impact patients' quality of life as well as being effective in medico-economic terms.\n\nThe aims of this study are to demonstrate that rivaroxaban is at least as effective, easier to use and more efficient than LMWH in patients with trauma to the lower limb requiring immobilisation and deemed to be at risk of venous thromboembolism (TRiP(cast) score ≥ 7). High-risk patients are randomized to receive either rivaroxaban or LMWH. They are followed up at 45 days and 90 days to assess the occurrence of thrombotic events or bleeding, as well as their satisfaction with the treatment received.",[60,92,27,93,94,95],"Deep Vein Thrombosis","Lower Limb Trauma","Thromboprophylaxis","Immobilisation",[97,98,99,100,101,102],"Emergency department","direct oral anticoagulant","rivaroxaban","Low-Molecular-weight heparin","randomized control trial","Prevent VTE","2026-06-22",{"date":105,"type":37},"2026-06-25",{"date":107,"type":37},"2024-07-19",{"date":109,"type":21},"2028-11-19",{"name":111,"class":112},"University Hospital, Angers","OTHER_GOV",37,{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100642274","decision-aid-for-anticoagulation-duration-after-unprovoked-venous-thromboembolism-100642274","NCT07659106","Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism","Enabling and Engaging Patients to Decide Indefinite Versus Short-Term Anticoagulation for Venous Thromboembolism (DECIDE-VTE)","DECIDE-VTE","Inclusion Criteria:\n\n* Age 18 years or older\n* First episode of objectively confirmed unprovoked or weakly provoked venous thromboembolism (VTE)\n* Objectively confirmed proximal deep vein thrombosis and\u002For segmental or greater pulmonary embolism\n* Completed at least 3 months of therapeutic anticoagulation and currently receiving anticoagulation\n* Enrollment within 12 months of diagnosis of the index\u002Fqualifying VTE event\n* Able to provide written informed consent\n* Able to participate in shared decision-making in English or French\n\nExclusion Criteria:\n\n* Recurrent unprovoked or weakly provoked VTE I(i.e. multiple unprovoked\u002Fweakly provoked VTE)\n* Index\u002Fqualifying VTE is a strongly provoked VTE (e.g., associated with major surgery, major trauma, plaster cast immobilization, or prolonged bed rest)\n* Index\u002Fqualifying VTE associated with a persistent strong provoking risk factor (e.g., active cancer or ongoing immobility)\n* Women at very low recurrence risk (HERDOO2 score 0-1)\n* High bleeding risk such that anticoagulation should be discontinued\n* Requirement for long-term anticoagulation for another indication (e.g., atrial fibrillation)\n* Prior dedicated long-term anticoagulation Decision Visit regarding anticoagulation duration",{"count":123,"type":21},850,[125],"NA","Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a common condition that is typically treated with blood thinners (anticoagulants). After completing at least 3 months of treatment for a first unprovoked or weakly provoked VTE, patients and clinicians must decide whether to stop anticoagulation or continue treatment for a longer period. Continuing anticoagulation reduces the risk of another blood clot but increases the risk of bleeding. Because both options involve important benefits and risks, this decision should reflect the patient's values and preferences.\n\nThe DECIDE-VTE study will evaluate whether a patient decision aid can improve decision-making for patients facing this choice. The decision aid provides evidence-based information about the risks and benefits of continuing versus stopping anticoagulation and includes a values clarification exercise to help patients identify what matters most to them.\n\nThis multicentre batched stepped-wedge cluster randomized trial will be conducted in 12 thrombosis clinics across Canada. Clinics will transition from usual care to implementation of the patient decision aid according to a randomized schedule. The primary outcome is decisional conflict immediately following the anticoagulation decision visit, measured using the Decisional Conflict Scale. Secondary outcomes include patient knowledge, treatment decisions, decisional regret, concordance with the chosen treatment strategy, recurrent venous thromboembolism, major bleeding, all-cause mortality, and implementation outcomes.",[128,129,27],"Venous Thromboembolism (VTE)","Deep Vein Thrombosis (DVT)",[66,131,132,133,134,135],"Patient Decision Aid","Shared Decision Making","Extended Anticoagulation","Decisional Conflict","Stepped-Wedge Cluster Randomized Trial","NOT_YET_RECRUITING","2026-06-19",{"date":139,"type":37},"2026-06-24",{"date":141,"type":21},"2026-09",{"date":143,"type":21},"2029-03",{"name":145,"class":44},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",5,{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100543556","association-of-anti-factor-xa-activity-with-venous-thromboembolism-in-critically-ill-patients-100543556","NCT06357403","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study","AntiXa-ICU","Inclusion Criteria:\n\n* Age over 18 years at the time of intensive care unit admission\n* Admission to a participating intensive care unit within the last 24 hours\n* Expected discharge is later than 48 hours after enrolment\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE\u002Fkg when given twice daily or of at least 150 IE\u002Fkg when given once daily\n* Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment\n* Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period\n* Estimated life expectancy below 48 hours or comfort terminal care order in place\n* Previously diagnosed heparin-induced thrombocytopenia\n* Pre-operative admission for elective surgery\n* Previous enrolment in the study",{"count":156,"type":21},1300,"The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and\u002For pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:\n\n* What is the association between antiXa and VTE?\n* What is the association between antiXa and symptomatic, respectively incidental, VTE?\n* How is pharmacological anticoagulation with enoxaparin related to measured antiXa?\n* What is the association between antiXa and bleeding complications.\n* What is the incidence of venous thromboembolism in patients treated at an intensive care unit?\n* How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit\u002Fhospital.",[159,27,160],"Thrombosis","Enoxaparin","2026-06-18",{"date":68,"type":37},{"date":164,"type":37},"2024-05-04",{"date":166,"type":21},"2027-08",{"name":168,"class":44},"Medical University of Vienna",3,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":192,"locationsCount":194},"100530220","data-clustering-study-with-artificial-intelligence-and-phenotyping-of-patients-with-acute-pulmonary-embolism-100530220","NCT06183944","Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism","Data Clustering Study With Artificial Intelligence and Phenotyping of Patients Who Presented With Acute Pulmonary Embolism","PEPITE","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Patient with acute pulmonary embolism in CHITS (hospitalised or not).\n\nExclusion Criteria:\n\n* Sub-segmental pulmonary embolisms ;\n* Patient opposition.",{"count":179,"type":21},2500,"The aim will be to identify clinically relevant phenotypes in patients with acute pulmonary embolism. Hierarchical clustering methods combined with unsupervised learning (machine learning) will be used to obtain groups of patients who are homogeneous at diagnosis. Evaluating their prognosis at 6 months (recurrence or chronic thromboembolic pulmonary hypertension), account the first 3 months of anticoagulant treatment, would provide an aid to medical decision-making.\n\nThis research will include a retrospective and a prospective parts. The retrospective part will include patients who have been admitted to CHITS for acute pulmonary embolism since 2019. For the prospective part, it is planned to include patients with same characteristics over the years 2024 and 2025. More than 2,500 patients are expected to be included.\n\nThis research will have no impact on current patient care. Data from consultations and various examinations carried out as part of care will be collected for six months post-diagnosis in order to meet the research objectives.",[27],[183,184,185],"Acute Pulmonary Embolism","Clustering with unsupervised learning","Therapeutic decision tool","2026-06-15",{"date":188,"type":37},"2026-06-16",{"date":190,"type":37},"2023-12-11",{"date":34,"type":21},{"name":193,"class":44},"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer",1,{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":194},"100447225","ventilationperfusion-petct-with-galligas-and-68ga-maa-for-regional-lung-function-assessment-after-pulmonary-embolism-100447225","NCT05103670","Ventilation\u002FPerfusion PET\u002FCT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism","EOLE","Inclusion Criteria:\n\n* Patient included in the RAMBO study, whose inclusion criteria are: Age ≥ 18 years; Patient treated with at least 3 months and up to 8 months of anticoagulation for an acute symptomatic PE diagnosed according the ESC and ACCP guidelines; Patients who have a PembQol score ≥ 10% and whose total scores for the subgroups Q1 (dyspnea) and Q4 (impact of daily life) are ≥ 10%.\n* Patients planned to be randomized\n* Abnormal conventional V\u002FQ scan at V1\n* Give consent to participate to the EOLE study\n\nExclusion Criteria:\n\n* Non inclusion criteria of the RAMBO trial:\n* Previsible inability to perform the effort test and\u002For PR\n* Presence of CTEPH according to international guidelines\n* Patients treated for acute PE with anticoagulants for more than 8 months\n* Active cancer or in remission for less than two years\n* Dyspnea post - COVID due to parenchymal injuries\n* Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae\n* Physical or psychological inability to undertake PR\n* Isolated or more distal segmental PE\n* Neuro-muscular disease with PR contraindication.\n* Cardiac insufficiency (unstable coronary artery disease)\n* Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension)\n* Chronic dyspnea MMRC ≥ 2 before PE\n* Cardiac or respiratory rehabilitation in the previous year\n* Indication to urgent PR within 6 months at the time of inclusion\n* Life expectancy of less than 12 months\n* Inability to give consent\n* Patient under guardianship or curatorship\n* Patient deprived of liberty by an administrative or judicial decision\n* Patient has not social security affiliation or who don't beneficiary of such social security\n\nAfter initial PR work up, patients with following criteria cannot be included:\n\n* Incapacity to perform the effort test\n* Effort test stopped because of hemodynamic intolerance\n* Cardiac failure discovered after PR work up","99 Years",{"count":204,"type":21},32,[125],"In patients with pulmonary embolism (PE), after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases.\n\nThe \"RAMBO\" trial is a French academic, multicenter, randomized (1:1 ratio), parallel arm, controlled, that aimed to assess the efficacy of pulmonary rehabilitation (PR) on the quality of life in patients with an acute symptomatic PE treated with anticoagulant therapy during at least 3 months and who present an impairment of quality of life and\u002For persistent dyspnea despite anticoagulant therapy.\n\nVentilation\u002FPerfusion (V\u002FQ) PET\u002FCT is a novel imaging modality for the assessment of regional lung function. The same carrier molecules as conventional V\u002FQ imaging are used, but they are labeled with 68Gallium, a ß+ isotope, instead of 99mTc, allowing acquisition of images with PET technology.\n\nThe EOLE study is an ancillary pilot study of the RAMBO trial, in which patients will benefit, in addition to the extensive work up scheduled as per study protocol, from a V\u002FQ PET\u002FCT scan before and after PR. The aim of the study is to assess the impact of PR on regional lung function with lung V\u002FQ PET\u002FCT imaging.",[27,208],"Dyspnea",[210,211,212],"Ventilation\u002Fperfusion PET\u002FCT","Galligas","68Ga-MAA",{"date":188,"type":37},{"date":215,"type":37},"2023-06-22",{"date":217,"type":21},"2026-12-22",{"name":219,"class":44},"University Hospital, Brest",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":239},"100440427","impact-on-quality-of-life-with-pulmonary-rehabilitation-after-pulmonary-embolism-rambo-study-100440427","NCT05015153","Impact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study","RAMBO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient treated with at least 3 months and up to 8 months of anticoagulation for symptomatic EP diagnosed according the ESC and ACCP guidelines.\n* Patients who have a PembQol score ≥ 10% and whose total scores for the subgroups Q7+8 (dyspnea) and Q4 (impact of daily life) are ≥ 10%.\n\nExclusion Criteria:\n\n* Presence of CTEPH according to international guidelines\n* Patients treated for acute PE with anticoagulants for more than 8 months\n* Active cancer or in remission for less than two years\n* Dyspnea post - COVID due to parenchymal injuries\n* Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae.\n* Physical or psychological inability to undertake PR\n* Isolated or more distal segmental PE\n* Neuro-muscular disease with PR contraindication.\n* Cardiac insufficiency (unstable coronary artery disease)\n* Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension)\n* Chronic dyspnea MMRC ≥ 2 before PE\n* Cardiac or respiratory rehabilitation in the previous year\n* Indication to urgent PR within 6 months at the time of inclusion\n* Life expectancy of less than 12 months\n* Inability to give consent\n* Patient under guardianship or curatorship\n* Patient deprived of liberty by an administrative or judicial decision\n* Patient has not social security affiliation or who don't beneficiary of such social security",{"count":228,"type":21},112,[125],"Pulmonary Embolism (PE) is a common and serious disease. Indeed, the annual incidence is 1\u002F1000 patients per year and the 3-month mortality is 10%, which is twice that of myocardial infarction. The treatment is based on anticoagulation for at least 3 months. However, after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases. Several mechanisms explain dyspnea and impairment of quality of life after PE, such as residual pulmonary artery obstruction, exercise deconditioning, depressive syndrome or development of a cardio-respiratory pathology. Pulmonary rehabilitation (PR) has been shown to be effective on dyspnea and quality of life and is included in the therapeutic management of chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) or pulmonary fibrosis. Furthermore, PR is also used after a myocardial infarction. However, PR after PE is still not included in therapeutic management of PE while outpatient management is recommended for the majority of patients after an acute PE episode. Study hypothesis is that PR has the potential to improve quality of life and dyspnea perception in patients who have received anticoagulation for at least 3 months after PE and who present an impairment of quality of life and\u002For a persistent dyspnea. This study presents several innovative aspects. First, to our knowledge, This study is the first large randomized trial assessing PR at least 3 months after acute symptomatic PE. Only one small randomized trial on 18 patients evaluating the impact of PR after PE has been published; as PR was performed just after the acute phase of PE in this trial, the clinical status improvement observed in this study could not be explained by PR alone, but also by anticoagulation. In this study, the investigators will include 112 patients at least 3 months after PE in order to exclude the bias related to anticoagulation effect. Second, This study is the first large randomized trial. Third, this study is the first that have the potential to demonstrate efficacy and safety of delayed PR after PE in patients with impaired quality of life due to persistent residual dyspnea.",[27,232],"Quality of Life and Dyspnea",{"date":188,"type":37},{"date":235,"type":37},"2022-05-11",{"date":237,"type":21},"2028-02-11",{"name":219,"class":44},6,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":261},"100544733","residual-pulmonary-vascular-obstruction-index-computed-with-ventilationperfusion-spectct-imaging-to-predict-the-risk-of-venous-thromboembolism-recurrence-in-patients-with-pulmonary-embolism-pronospect-100544733","NCT06372730","Residual Pulmonary Vascular Obstruction Index Computed With Ventilation\u002FPerfusion SPECT\u002FCT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT)","Residual Pulmonary Vascular Obstruction (RPVO) Index Computed With Ventilation\u002FPerfusion SPECT\u002FCT Imaging to Predict the Risk of Venous Thromboembolism (VTE) Recurrence in Patients With Pulmonary Embolism (PE)","PRONOSPECT","Inclusion Criteria:\n\n* Patients ≥ 18 years,\n* who experienced an objectively proven PE,\n* who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.\n\nExclusion Criteria:\n\n* Unwilling or unable to give written informed consent (protected adults, under tutorship or curatorship)\n* Patients deprived of their liberty by a judicial or administrative decision, patients undergoing psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and patients admitted to a health or social establishment for purposes other than research\n* No Social security affiliation\n* Isolated DVT\n* Pregnant women and parturients\n* Other indication for anticoagulant therapy (e.g. atrial fibrillation, mechanic valve)\n* Life expectancy \\\u003C 6 months\n* Any patients for whom there is a strong indication to treat longer than 6 months:\n\n  * PE provoked by a major persistent factor (e.g. cancer)\n  * Recurrent unprovoked PE\n\nPE provoked by a major transient risk factor (e.g. surgery with general anesthesia for greater than 30 min, confined to bed in hospital for at least 3 days with an acute illness, cesarean section)\n\nAND none of the following persistent factors :\n\n* BMI ≥ 30\n* Chronic respiratory disease\n* Chronic inflammatory disease (e.g., ulcerative colitis, rheumatoid arthritis, etc.)\n* Hepatocellular insufficiency\n* Renal insufficiency with creatinine clearance \\\u003C 60 mL\u002Fmin\n* Chronic or persistent immobilization",{"count":249,"type":21},665,[125],"Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk. Little is known about this last group.\n\nAnticoagulation is efficient to prevent recurrence but is currently not recommended for patient with an intermediate risk of recurrence.\n\nIdentifying risk factors of recurrent PE remains a major issue to identify sub-groups of patients who would require lifelong anticoagulation.\n\nIn 30-40% of cases, PE patients develop residual pulmonary vascular obstruction (RPVO), which has been found to be associated with an increased recurrence risk. This last observation was mostly reported in patients with unprovoked PE (patients with high risk of recurrence) and RPVO was measured using conventional planar lung scan.\n\nIn patients with an intermediate risk of recurrence, the impact of RPVO has been much less studied. In addition, the definition of RPVO was variable according to studies and correlation between RPVO burden and recurrence risk has not been clearly demonstrated. This might be explained by the inherent limitation of RPVO quantification using conventional planar imaging, which is only based on a visual estimation on 2-dimensional images.\n\nVentilation\u002FPerfusion Single Photon Emission Computed Tomography (V\u002FQ SPECT\u002FCT) is a new method of scintigraphic image acquisition that offers the advantage of 3-dimensional imaging, enabling more accurate and reproducible quantification of RPVO.\n\nThe main hypothesis of this study is that in patients with PE at intermediate risk of recurrence, RPVO computed with V\u002FQ SPECT\u002FCT imaging may be an important predictor of recurrence.",[27,60],[254],"venous thromboembolism recurrence","2026-06-12",{"date":186,"type":37},{"date":258,"type":37},"2024-06-11",{"date":143,"type":21},{"name":219,"class":44},13,{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":45},"100642788","risk-stratification-and-prognostic-value-of-right-ventricular-dysfunction-screening-using-transthoracic-echocardiography-in-acute-pulmonary-embolism-100642788","NCT07647497","Risk Stratification and Prognostic Value of Right Ventricular Dysfunction Screening Using Transthoracic Echocardiography in Acute Pulmonary Embolism","RVD-PE","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Patients with a confirmed diagnosis of acute pulmonary embolism.\n* Patients who underwent transthoracic echocardiographic assessment for right ventricular dysfunction.\n\nExclusion Criteria:\n\n* Patients younger than 18 years.\n* Patients with incomplete clinical data.\n* Patients who did not undergo transthoracic echocardiography.",{"count":228,"type":21},"This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.",[27],[273,274,27,275],"Right Ventricular Dysfunction","Echocardiography","Risk Stratification","2026-06-10",{"date":186,"type":37},{"date":279,"type":21},"2026-06-01",{"date":281,"type":21},"2026-11-30",{"name":283,"class":44},"Sohag University",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":304},"100520388","the-peerless-ii-study-100520388","NCT06055920","The PEERLESS II Study","PEERLESS II: RCT of FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism","Inclusion Criteria:\n\n1. Age at enrollment ≥ 18 years\n2. Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality\n3. RV dysfunction, as defined as one or more of the following: RV\u002FLV ratio ≥ 0.9 or RV dilation or hypokinesis\n4. At least two additional risk factors, identified by at least one measure in two separate categories noted below:\n\n   a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate \\> 100 bpm b. Biomarker: i. Elevated\\* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated\\* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol\u002FL \\* Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation \\\u003C 90% on room air ii. Supplemental O2 requirement ≥ 4 L\u002Fmin iii. Respiratory rate ≥ 20 breaths\u002Fmin iv. mMRC score \\> 0\n5. Symptom onset within 14 days of confirmed PE diagnosis\n6. Willing and able to provide informed consent\n\nExclusion Criteria:\n\n1. Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin\n2. Presentation with hemodynamic instability\\* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following\n\n   1. Cardiac arrest OR\n   2. Systolic BP \\\u003C 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR\n   3. Systolic BP \\\u003C 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis \\* Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.\n3. Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated\n4. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental\u002Fsubsegmental distribution, predominately chronic clot)\n5. End stage medical condition with life expectancy \\\u003C 3 months, as determined by the Investigator\n6. Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study\n7. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1\n8. If objective testing was performed\\*, estimated RV systolic pressure \\> 70 mmHg on standard of care echocardiography \\* If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion\n9. Administration of advanced therapies (thrombolytic bolus, thrombolytic drip\u002Finfusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment\n10. Ventricular arrhythmias refractory to treatment at the time of enrollment\n11. Known to have heparin-induced thrombocytopenia (HIT)\n12. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling\n13. Subject is currently pregnant\n14. Subject has previously completed or withdrawn from this study",{"count":292,"type":21},1200,[125],"This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.",[27],"2026-06-09",{"date":276,"type":37},{"date":299,"type":37},"2023-11-17",{"date":301,"type":21},"2026-07",{"name":303,"class":77},"Inari Medical",83,{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":330,"locationsCount":194},"100642262","pulmonary-artery-pressure-in-predicting-pulmonary-embolism-in-patients-presenting-to-the-emergency-department-with-dyspnea-100642262","NCT07641400","Pulmonary Artery Pressure in Predicting Pulmonary Embolism in Patients Presenting To The Emergency Department With Dyspnea","The Diagnostic Value of The Difference Between Prior and Immediate Pulmonary Artery Pressure in Predicting Pulmonary Embolism in Patients Presenting To The Emergency Department With Dyspnea","Inclusion Criteria:\n\n* Presenting to the emergency department with dyspnea between the specified dates,\n* Being 18 years of age or older,\n* Being evaluated in the emergency department with a preliminary diagnosis of pulmonary embolism,\n* Having a recorded pulmonary artery pressure measurement at the time of hospital admission,\n* Having a previous pulmonary artery pressure measurement in the patient's records,\n* Having sufficient and complete clinical, laboratory, imaging, and echocardiography data available for the study.\n\nExclusion Criteria:\n\n* Patients under 18 years of age,\n* Lack of pulmonary artery pressure data from the time of emergency admission or from the previous period,\n* Lack of necessary clinical, laboratory, or imaging data for pulmonary embolism evaluation,\n* In cases of repeated admissions for the same patient, only the first suitable admission will be considered; other admissions will be excluded from the study,\n* Patients whose data is unavailable in the record system or whose data is insufficient to be analyzed for research purposes.Inclusion Criteria for the Study",{"count":313,"type":21},80,"The aim of this study is to determine the usability of echocardiographic PAP changes obtained from emergency department records in the early risk stratification of pulmonary embolism.",[316,317,27],"Emergency Department Patients","Pulmonary Hypertension",[319,320,321,322,323],"emergency deparment patients","pulmonary hypertension","pulmonary embolism","dispnea","chest pain","2026-06-06",{"date":326,"type":37},"2026-06-11",{"date":279,"type":21},{"date":329,"type":21},"2026-10-01",{"name":331,"class":44},"Antalya Health Sciences University",{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":340,"studyType":56,"phases":4,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":351},"100562236","inari-vision-registry-100562236","NCT06600542","Inari VISION Registry","Inclusion Criteria:\n\n1. Willing and able to provide informed consent per institution and geographical requirements\n2. Has received treatment with an eligible Inari Medical device. NOTE: If patients are consented prior to their procedure and the procedure does not take place, the patient will be considered a screen failure.\n3. Currently within enrollment window relative to their procedure\n4. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Is or will be inaccessible for registry follow-up\n2. Meets exclusion criteria required by local requirements\n3. Current or planned participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this registry\n4. Is pregnant or breastfeeding at the time of enrollment",{"count":339,"type":21},1000,"180 Days","This registry is a global prospective, non-randomized, multicenter, observational, active post-market data collection of Inari Medical devices and products.",[27],"2026-06-03",{"date":345,"type":37},"2026-06-04",{"date":347,"type":37},"2025-03-07",{"date":349,"type":21},"2029-12-31",{"name":303,"class":77},10,{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":376},"100561320","the-persevere-study-100561320","NCT06588634","The PERSEVERE Study","Inclusion Criteria:\n\n1. Age at enrollment ≥18 years\n2. Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery\n3. High-risk class of acute PE\n4. RV dysfunction, as defined RV\u002FLV ratio ≥1.0\n5. Willing and able to provide informed consent, or if unable, through a Legal Authorized Representative, with permitting research without prior consent as a third option (for Europe and UK sites only), provided compliance with IRB\u002FEC approvals and adherence to regulatory, ethical and national standards\n\nExclusion Criteria:\n\n1. Prolonged cardiac arrest with loss of consciousness associated with neurological deficit.\n2. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention\n3. Known pre-existing CTEPH, or CT signs of chronic PE that may point to pre-existing CTEPH\n4. Recent stroke (\\\u003C14 days)\n5. Recent cranial or spinal surgery (\\\u003C14 days)\n6. Life-threatening active bleeding or hemorrhage into a critical area\n7. Known intracranial tumor\n8. End-stage medical condition with life expectancy \\\u003C3 months (irrespective of the severity of acute PE), as determined by the Investigator\n9. Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated\n10. Inability to anticoagulate the patient, or known to have heparin-induced thrombocytopenia (HIT)\n11. Current participation in another drug or device study that may interfere with the conduct of this trial\n12. Ventricular arrhythmias refractory to treatment at the time of enrollment\n13. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments), including a contraindication to use of FlowTriever System per local approved labeling\n14. Subject is part of a vulnerable population (e.g., currently pregnant, breastfeeding or incarcerated) per local definitions\n15. Subject was previously enrolled in this study\n16. Subject has received prior thrombolytic (systemic or catheter-directed) therapy for any reason or thrombectomy (surgical or catheter-based) therapy for index PE, within 30 days prior to randomization",{"count":359,"type":21},200,[125],"Randomized Controlled Trial of High-Risk Pulmonary Embolism Comparing FlowTriever System vs. Standard of Care",[27,363],"Pulmonary Thromboembolism",[365,27,366,367,368,66],"PE","FlowTriever","CDT","Catheter Directed Thrombolysis","2026-06-02",{"date":345,"type":37},{"date":372,"type":37},"2024-12-16",{"date":374,"type":21},"2028-02",{"name":303,"class":77},26,{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":387,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":194},"100443148","point-of-care-ultrasound-in-predicting-adverse-outcomes-in-emergency-department-patients-with-acute-pulmonary-embolism-100443148","NCT05050617","Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism","Inclusion Criteria:\n\n* Age \\>= 18 years of age\n* ED diagnosis of acute pulmonary embolism with identification on CT imaging\n\nExclusion Criteria:\n\n* Age \\\u003C18 years of age\n* Inability to provide informed consent\n* Incarceration\n* Current PE previously diagnosed prior to index ED visit",{"count":384,"type":21},250,"This study is an observational, prospective study examining the role point-of-care echocardiography of predicting short term adverse outcomes in emergency department patients with acute pulmonary embolism.\n\nThe primary objective is to assess the diagnostic performance of ultrasound-guided measures of right ventricular dilation (RVD) and strain in predicting clinical outcomes in acute PE.\n\nThe secondary objective is to investigate the utility of combining ultrasound-guided measures of RVD and the pulmonary embolism severity index (PESI) score in predicting adverse outcomes in acute PE.",[27],{"date":343,"type":37},{"date":389,"type":37},"2021-09-09",{"date":391,"type":21},"2026-12",{"name":393,"class":44},"WellSpan Health",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":406,"conditions":407,"keywords":415,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":426},"100382700","phase-4-clinical-surveillance-vs-anticoagulation-for-low-risk-patients-with-isolated-subsegmental-pulmonary-embolism-100382700","NCT04263038","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial","SAFE-SSPE","Inclusion Criteria:\n\n1. Informed Consent as documented by signature\n2. Age ≥18 years\n3. Objective diagnosis of symptomatic or asymptomatic isolated SSPE\n\nExclusion Criteria:\n\n1. Presence of leg deep vein thrombosis (DVT) or upper extremity DVT (subclavian vein or above)\n2. Active cancer, defined as cancer treated with surgery, chemotherapy, radiotherapy, or palliative care during the last 6 months\n3. ≥1 prior episode of unprovoked VTE (absence of a transient or permanent risk factor)\n4. Clinical instability (systolic blood pressure \\\u003C100 mm Hg or arterial Oxygen saturation \\\u003C92% at ambient air) at the time of presentation\n5. Active bleeding or at high risk of bleeding\n6. Severe renal failure (creatinine clearance \\\u003C30ml\u002Fmin)\n7. Severe liver insufficiency (Child-Pugh B or C)\n8. Concomitant use of strong CYP3A4 inhibitors or strong CYP3A4 inducers\n9. Known hypersensitivity to rivaroxaban\n10. Need for therapeutic anticoagulation for another reason\n11. Therapeutic anticoagulation for \\>72 hours for any reason at the time of screening\n12. Hospitalized for \\>72 hours prior to the diagnosis of isolated SSP (hospital-acquired VTE)\n13. Known pregnancy or breast feeding (pregnancy test to be performed for women of childbearing potential)\n14. Lack of safe contraception in women of childbearing potential\n15. Refusal or inability to provide informed consent\n16. Prior enrolment in this trial",{"count":403,"type":21},276,[405],"PHASE4","The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial. Whether isolated SSPE represents \"true\" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain. Despite growing evidence from observational studies that withholding anticoagulation may be a safe option in selected patients with isolated SSPE (i.e., those without concomitant deep vein thrombosis, cancer, etc.), most patients with isolated SSPE receive anticoagulant treatment, which is associated with an increased risk of bleeding. The overall objective of the randomized controlled SAFE-SSPE trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation compared to anticoagulation treatment in low-risk patients with isolated SSPE.",[27,408,409,410,411,412,60,413,414],"Embolism","Embolism and Thrombosis","Lung Diseases","Cardiovascular Diseases","Respiratory Tract Diseases","Anticoagulant-induced Bleeding","Bleeding",[416],"subsegmental pulmonary embolism","2026-05-20",{"date":419,"type":37},"2026-05-22",{"date":421,"type":37},"2020-05-15",{"date":423,"type":21},"2028-05",{"name":425,"class":44},"Drahomir Aujesky",40,{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":436,"conditions":437,"keywords":438,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":444,"leadSponsor":445,"locationsCount":194},"100637111","strategy-pe-real-world-treatment-strategies-for-intermediate-high-risk-pulmonary-embolism-100637111","NCT07603700","STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism","Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study","STRATEGY-PE","Inclusion Criteria:\n\n* Age unlimited (reflecting real-world population).\n* Symptom duration of acute PE ≤ 14 days.\n* Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.\n* Defined as Intermediate-High Risk PE meeting all of the following:\n* RV\u002FLV ratio ≥ 0.9 (by CT or Echocardiography).\n* Elevated cardiac biomarkers (Troponin \\> 99th percentile or BNP \\> 100 pg\u002FmL).\n* Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).\n* Able to provide informed consent and complete follow-up.\n\nExclusion Criteria:\n\n* Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.\n* Unable to obtain baseline or follow-up CTPA imaging.\n* (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).",{"count":156,"type":21},"This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.",[27,60],[183,439,66,440],"Intermediate-High Risk","Thrombolysis","2026-05-17",{"date":419,"type":37},{"date":279,"type":21},{"date":349,"type":21},{"name":446,"class":44},"Nanjing First Hospital, Nanjing Medical University",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":457,"conditions":458,"keywords":459,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":426},"100484674","phase-3-pulmonary-embolism---thrombus-removal-with-catheter-directed-therapy-100484674","NCT05591118","Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy","PE-TRACT","Inclusion Criteria:\n\n1. Symptomatic PE diagnosed by contrast-enhanced CT angiography with involvement of a main or lobar pulmonary artery branch; and\n2. Right ventricular (RV) dilation as defined by the presence of an RV\u002FLeft ventricular ratio \\> 1 on CT angiography\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Systolic blood pressure \\\u003C 90 mmHg for \\>15 consecutive minutes or \\> 40 mmHg drop from baseline, or vasopressor requirement for blood pressure support (i.e., massive PE), occurring within 1 hour prior to eligibility assessment.\n3. Symptom duration \\> 14 days for the current PE episode\n4. Irreversible INR \\> 3\n5. Irreversible Thrombocytopenia (Platelets \\\u003C 50,000\u002Fmicroliter)\n6. Creatinine \\> 2.0 mg\u002Fdl\n7. Hemoglobin \\\u003C 7.0 g\u002Fdl\n8. Pregnancy (positive urine or blood pregnancy test (a pregnancy test must be obtained within 7 days prior to randomization in people of childbearing potential))\n9. Allergy or hypersensitivity to Recombinant Tissue Plasminogen Activator (rt-PA), or iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used\n10. Life expectancy \\\u003C 1 year\n11. Chronic inability to independently walk prior to the current PE episode (e.g. wheelchair dependent, walker or cane dependent, paraplegic, and\u002For bed-bound)\n12. Allergy to heparin or history of Heparin-Induced Thrombocytopenia (HIT)\n13. Unable or unwilling to provide informed consent\n14. Major contraindication or unsuitability for all CDT methods available at the Clinical Center",{"count":455,"type":21},500,[24],"PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.",[27],[460],"Catheter-Directed Therapy (CDT)","2026-05-15",{"date":463,"type":37},"2026-05-18",{"date":465,"type":37},"2023-07-17",{"date":467,"type":21},"2027-08-04",{"name":469,"class":44},"NYU Langone Health",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":488},"100423775","study-of-the-long-term-safety-and-outcomes-of-treating-pulmonary-embolism-with-the-indigo-aspiration-system-100423775","NCT04798261","Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System","STRIKE-PE: A Prospective, Multicenter Study of the Indigo™ Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism","Inclusion Criteria:\n\n1. Clinical signs and symptoms consistent with acute PE with duration of 14 days or less\n2. RV\u002FLV ratio ≥ 0.9 assessed by diagnostic computed tomographic angiography (CTA) or echocardiogram\n3. Frontline endovascular treatment with the Indigo Aspiration System per IFU\n4. Patient is ≥ 18 years of age\n5. Informed consent obtained per Institutional Review Board\u002FEthics Committee requirements\n\nExclusion Criteria:\n\n1. Contraindication to systemic or therapeutic doses of anticoagulants (e.g. heparin)\n2. Stage IV (metastatic) cancer, active lung cancer or previous history of surgery in the affected lung(s) or chest radiation\n3. Known serious, uncontrolled sensitivity to radiographic agents\n4. Life expectancy \\\u003C 180 days\n5. Patients on ECMO\n6. Pregnant patients\n7. Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies\n8. Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study",{"count":478,"type":21},1500,"The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).",[27],"2026-05-14",{"date":463,"type":37},{"date":484,"type":37},"2021-06-25",{"date":374,"type":21},{"name":487,"class":77},"Penumbra Inc.",76,{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":498,"conditions":499,"keywords":502,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":78},"100540699","emergency-medicine-pulmonary-embolism-testing-multicentre-study-100540699","NCT06320236","Emergency Medicine Pulmonary Embolism Testing Multicentre Study","EMPET","Inclusion Criteria:\n\n* Emergency department patient who is tested by an emergency physician for PE\n\nExclusion Criteria:\n\n* Patient is \\\u003C 18 years of age\n* No documentation of whether PE is the most likely diagnosis\n* D-dimer is not tested or else not resulted during the emergency visit\n* The D-dimer level is known before documentation of whether PE is the most likely diagnosis\n* The D-dimer is ordered prior to the physician assessing the patient\n* The patient has previously registered that they opt out of all research at the participating site\n* The patient leaves against medical advice\n* The patient has had PE or deep vein thrombosis imaging (CT pulmonary angiogram, ventilation-perfusion scan or lower limb ultrasound) within prior 30 days\n* There is a new (non-PE) indication for anticoagulation\n* The patient was initiated on treatment for presumed PE prior to PE testing\n* The patient has previously been enrolled into the study\n* The patient has a prior history of lower extremity deep vein thrombosis without availability of a baseline ultrasound scan\n* The patient was transferred from another hospital organization\n* The patient does not reside in Ontario\n* The patient has no valid Ontario Health Insurance Plan card",{"count":497,"type":21},4000,"It is important to diagnose pulmonary embolism in a timely manner to prevent death and long-term disability. More than half a million people (4-5% of emergency department patients) are tested for pulmonary embolism, although the positive rate is low. Imaging for PE testing exposes patients to radiation, is expensive, adds time to the emergency visit, and can lead to a false positive diagnoses. Existing protocols aimed at reducing unnecessary pulmonary embolism imaging are complex and seldom used by emergency physicians. Too many patients undergo unnecessary pulmonary embolism imaging.\n\nA new tool (called Adjust-Unlikely) could safely reduce pulmonary embolism imaging in Canada. A research group composed of researchers, emergency physicians, and patients developed the Adjust-Unlikely clinical decision rule: a rule which has been customized for emergency physicians and emergency patients. Adjust-Unlikely is highly sensitive at the bedside, meaning there are very few false negative results.\n\nThe study aim is to prospectively validate Adjust-Unlikely pulmonary embolism testing in emergency patients with suspected pulmonary embolism.",[27,500,501],"D-dimer","Diagnosis",[500,27,503,504,505],"Adjust-Unlikely","Diagnostic","Emergency Medicine","2026-04-15",{"date":508,"type":37},"2026-04-20",{"date":510,"type":37},"2024-01-01",{"date":512,"type":21},"2027-09-30",{"name":514,"class":44},"Dr. Kerstin de Wit",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":522,"targetDuration":524,"studyType":56,"phases":4,"briefSummary":525,"conditions":526,"keywords":527,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":539},"100507008","post-market-celect-platinum-vena-cava-filter-and-gunther-tulip-retrieval-set-study-100507008","NCT05881798","Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study","Post-Market Celect Platinum Vena Cava Filter and Günther Tulip Retrieval Set Study","Inclusion Criteria:\n\n* A patient dataset is deemed suitable for inclusion if the patient has a procedure where a Celect Platinum Vena Cava Filter is placed\n* Subject has not previously participated in the Cook MDR-2126 study.\n\nExclusion Criteria:\n\n* Patients will be excluded from enrollment if the patient or his\u002Fher legally authorized representative objects to collection and processing of his\u002Fher data or is not willing to sign the Informed Consent.",{"count":523,"type":21},82,"5 Years","This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and continued acceptability of the benefit:risk ratio. Additionally, the study intends to evaluate longer-term (i.e., up to 5 years) outcome data while the filter is indwelling.",[92,60,27],[528,529],"Celect Platinum Vena Cava Filter","Gunther Tulip Vena Cava Filter Retrieval Set","2026-04-14",{"date":532,"type":37},"2026-04-17",{"date":534,"type":37},"2025-06-02",{"date":536,"type":21},"2030-12",{"name":538,"class":77},"Cook Research Incorporated",7,{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":548,"targetDuration":550,"studyType":56,"phases":4,"briefSummary":551,"conditions":552,"keywords":553,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":194},"100527146","ultrasound-assisted-catheter-directed-thrombolysis-for-acute-intermediate-high-risk-pulmonary-embolism-100527146","NCT06143969","Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism","Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism (USAT IH-PE): Impact on Short- and Long-term Outcome, a Multi-center Experience. An Observational Retrospective and Prospective Multi-center Study","USAT IH-PE","Inclusion Criteria\n\n* Patients admitted with acute intermediate-high risk PE, defined according to ESC guidelines\n* Symptoms onset within previous 14 days associated or not with deep venous thrombosis\n* Confirmation of the PE by contrast-enhanced computed tomography of the chest with embolus located in at least one main or proximal lower lobe pulmonary artery\n* Echocardiographic parameters of RV disfunction\n* Patients with high-risk PE or hemodynamic deterioration on anticoagulation, who have absolute contraindications (high bleeding risk) to systemic thrombolysis and symptoms onset during the last 14 days. Patients with surgery-related embolic complications are also included (within 48 hours).\n\nExclusion Criteria\n\n* Age \\\u003C 18 years old\n* Patients unable to give informed consent\n* Pregnancy\n* Patients received fibrinolytic drugs in the preceding 4 days\n* Bleeding diathesis\n* Known bleeding disorder\n* Low platelet count (\\\u003C 100.000\u002FuL\n* Gastrointestinal bleeding in the preceding 3 month\n* Any ongoing known presence of malignant neoplasia months\n* Advanced chronic kidney disease (defined as 11.000\u002FuL)\n* Gastrointestinal bleeding in the preceding 3 month\n* Any ongoing known presence of malignant neoplasia at admission with survival rate \\\u003C 6\n* Advanced chronic kidney disease (defined as eGFR \\\u003C 30 ml\u002Fmin or on dialysis)",{"count":549,"type":21},180,"6 Months","The purpose of this retrospective and prospective multicenter study is to evaluate the incidence of pulmonary hypertension (PH) within 6 months from ultrasound-assisted, Catheter-directed Thrombolysis for acute intermediate- high-risk Pulmonary Embolism",[27],[321,554,555,556],"intermediate high-risk","Ultrasound-assisted","Catheter-directed Thrombolysis","2026-04-13",{"date":559,"type":37},"2026-04-16",{"date":561,"type":37},"2022-11-28",{"date":563,"type":21},"2027-03-31",{"name":565,"class":44},"Niguarda Hospital",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":22,"phases":574,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":194},"100574015","timing-of-venous-thromboembolism-prophylaxis-in-patients-with-hypertensive-intracerebral-hemorrhage-100574015","NCT06753786","Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage","Early or Delayed Initiation of Venous Thromboembolism Prophylaxis With Heparin in Patients With Hypertensive Intracerebral Hemorrhage","Inclusion Criteria:\n\n* the presence of hypertensive intracerebral hemorrhage\n\nExclusion Criteria:\n\n* Intracerebral hemorrhage expansion detected on the basis of a computed tomography scan of the brain 12-24 hours after a hospital admission (i.e. before the initiation of venous thromboembolism prophylaxis with heparin)\n* Being on an anticoagulant during preadmission period and on day of hospital admission\n* Death within the first 2 days after hospital admission\n* Detection of venous thromboembolism in a patient at the moment of hospital admission\n* Surgical management of hypertensive intracerebral hemorrhage before the beginning of venous thromboembolism prophylaxis using heparin\n* The presence of a malignancy (cancer) in a patient at the moment of hospital admission",{"count":359,"type":21},[125],"The objective of this randomized clinical trial is to evaluate the safety and efficiency of different anticoagulation schemes with heparin for venous thromboembolism prevention in patients with hypertensive intracerebral hemorrhage. The main questions it aims to answer are:\n\n* What is the optimal time for the beginning of anticoagulation with heparin to efficiently prevent venous thromboembolism in patients with hypertensive intracerebral hemorrhage? Early beginning (within the first 2 days but not earlier than 12 hours after the admission of a patient) or delayed beginning (on the third day after the admission of a patient)?\n* Which of the two timeframes (early or delayed) for anticoagulation beginning is the most safe in terms of bleeding complications including intracerebral hemorrhage expansion?\n\nResearchers will compare the results of early and delayed start of anticoagulation using heparin in patients with hypertensive intracerebral hemorrhage to define the optimal start time for anticoagulation that provides the most favourable efficiency\u002Fsafety profile.\n\nParticipants will:\n\n* Undergo a computed tomography (CT) scan of the brain on hospital admission and then 12-24 hours after the hospital admission and 24 hours after the beginning of venous thromboembolism prophylaxis using heparin;\n* Undergo the ultrasound examination of lower extremity deep veins on hospital admission and then once every 7 days;\n* Receive prophylactic doses of low molecular weight heparin or unfractionated heparin either beginning within the first 2 days but not earlier than 12 hours after the hospital admission or starting on the 3rd day after the hospital admission.",[60,27,577,92],"Intracerebral Hemorrhage",[579,580,30,581,582,66,583,584],"Prophylaxis","Deep vein thrombosis","Venous thromboembolism","Intracerebral hemorrhage","Low molecular weight heparin","Unfractionated heparin","2026-03-22",{"date":587,"type":37},"2026-03-24",{"date":589,"type":37},"2024-10-21",{"date":591,"type":21},"2028-12-31",{"name":593,"class":44},"Pirogov Russian National Research Medical University",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":22,"phases":602,"briefSummary":603,"conditions":604,"keywords":612,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":194},"100528865","interest-of-the-chair-lift-test-in-the-prognostic-evaluation-of-pulmonary-embolism-a-single-center-open-prospective-study-100528865","NCT06166329","Interest of the Chair Lift Test in the Prognostic Evaluation of Pulmonary Embolism: a Single-center Open Prospective Study","SIT-EP","Inclusion Criteria:\n\n* Diagnosis of pulmonary embolism according to clinical algorithm, confirmed by thoracic angioscan or ventilation perfusion (V\u002FP) scan,\n* Non-serious pulmonary embolism, not requiring intensive care (thrombectomy or fibrinolysis not considered).\n* sPESI score ≥ 1 \\[or = 0 with elevated troponin or presence of markers of VD dysfunction, or = 0 with need for hospitalization due to comorbidities unrelated to PE (social isolation, comprehension disorders, intercurrent infection, chronic renal failure, advanced cancer...)\n* Patients with no contraindications to chair lift testing (no O2 at the time of testing).\n* Effective anticoagulation for at least 1 hour.\n\nExclusion Criteria:\n\n* sPESI score = 0 with outpatient referral.\n* Diagnostic confirmation of Pulmonia Embolism by thoracic angioscan or scintigraphy more than 24h after suspicion of diagnosis.\n* Hospitalization \\> 24h after introduction of anticoagulation, with subsequent confirmation by scintigraphy.\n* Any sign of serious Pulmonia Embolism, requiring hospitalization in an intensive care unit.\n* Asymptomatic Pulmonia Embolism discovered by chance",{"count":549,"type":21},[125],"The objective of the study is to evaluate the prognostic performance of the chair lift test in the initial assessment of the severity of non-severe pulmonary embolism in hospitalized patients, in comparison with the current pulmonary embolism risk stratification score using the sPESI score refined by the use of cardiac biomarkers and right ventricular dysfunction",[605,27,606,607,608,609,610,611],"Non-severe Pulmonary Embolism","Non-high-risk Pulmonary Embolism","Pulmonary Embolism Acute","Prognostic Stratification","Risk Assessment in Pulmonary Embolism","Functional Exercise Testing","Early Prognostic Evaluation",[27,613,275,614,615,616,617,273,618,619,620,621,622,623],"Prognostic Evaluation","sPESI Score","Chair Stand Test","One-Minute Sit-to-Stand Test","Functional Capacity","Cardiac Biomarkers","Troponin","NT-proBNP","Early Mortality","Ambulatory Management","Hospitalized Patients",{"date":625,"type":37},"2026-02-17",{"date":627,"type":37},"2024-02-09",{"date":629,"type":21},"2027-02",{"name":631,"class":44},"University Hospital, Rouen",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":22,"phases":642,"briefSummary":643,"conditions":644,"keywords":646,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":78},"100545761","thrombin-generation-parameters-and-bleeding-in-patients-treated-with-anticoagulants-for-cancer-associated-thrombosis-100545761","NCT06386107","Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis","Association Between Thrombin Generation Parameters and the Risk of Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis (CAT) (a Multicenter Study)","CATforCAT","Inclusion Criteria:\n\n* Patients with active cancer, as defined by current French recommendations (Mahé I et al Rev Mal Respir 2021)\n* Presenting acute proximal deep vein thrombosis of the lower limb (DVT) and\u002For proximal pulmonary embolism (at least segmental) (PE), confirmed by objective tests (Doppler ultrasound in the event of DVT; lung scintigraphy or CT scan in the event of PE)\n* No contraindication for anticoagulant treatment at a curative dose at the time of inclusion\n\nExclusion Criteria:\n\n* Patients participating in a therapeutic clinical trial with a blinded therapy or an open-label therapeutic trial who are included in the experimental treatment group.\n* Patients already on anticoagulant at a curative dose for valvular or rhythmic embolic disease or a history of venous thromboembolic disease\n* Hematological malignancies\n* Patients with a contraindication to anticoagulant treatment on inclusion\n* Patient whose relay by DOAC has already been carried out.",{"count":641,"type":21},212,[125],"Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of bleeding in the first 6 months. Most of the guidelines propose to integrate the bleeding risk in the choice of therapies. Thrombin generation assay (TGA) reflects an overall hemostatic response and could be a useful biomarker. Proven on the thrombotic side in the CAT population, useful in the assessment of the bleeding risk of hemophiliac patients, the TGA is emerging as a tool. The investigators to measure TGA in cancer patients included prospectively, having recently developed a CAT and to evaluate the association between the measurement and the risk of hemorrhagic complication under anticoagulant during the first 6 month of treatment.",[645,27,159],"Cancer",[645,159,647],"Anticoagulant associated bleeding","2026-02-11",{"date":650,"type":37},"2026-02-12",{"date":652,"type":37},"2025-09-02",{"date":654,"type":21},"2028-07",{"name":656,"class":44},"Centre Hospitalier Universitaire de Saint Etienne"]